On July 23, 2021, the CDC issued a report in which it stated, “Candida auris is an emerging, often multidrug-resistant yeast that is highly transmissible, resulting in health care–associated outbreaks, especially in long-term care facilities. Skin colonization with C. auris allows spread and leads to invasive infections, including bloodstream infections, in 5%–10% of colonized patients.”
“Three major classes of antifungal medications exist for treating invasive infections: azoles (e.g., fluconazole), polyenes (e.g., amphotericin B), and echinocandins. Approximately 85% of C. auris isolates in the United States are resistant to azoles, 33% to amphotericin B, and 1% to echinocandins, based on tentative susceptibility breakpoints. Echinocandins are thus critical for treatment of C. auris infections and are recommended as first-line therapy for most invasive Candida infections. Echinocandin resistance is a concerning clinical and public health threat, particularly when coupled with resistance to azole and amphotericin B (pan-resistance).”
” … two simultaneous, independent clusters of pan- or echinocandin-resistant C. auris cases in patients with overlapping inpatient health care exposures and without previous echinocandin use provide the first evidence suggesting that pan- or echinocandin-resistant C. auris strains might have been transmitted in U.S. health care settings. Surveillance, public health reporting, and infection control measures are critical to containing further spread. Clinicians should consider early antifungal susceptibility testing in patients with C. auris infection, especially in those with treatment failure.”
In response to the CDC report, the Association for Professionals in Infection Control and Epidemiology (APIC) issued a statement on July 28, 2021 in which it “urges healthcare facilities to implement aggressive infection prevention and control measures to ensure this pathogen does not become embedded in U.S. healthcare settings … With few ways to treat it, preventing C. auris from spreading is our best and only option. Healthcare facilities must deploy robust infection prevention programs, which include proper staffing of dedicated professionals known as infection preventionists, to guide infection prevention and control efforts.”
“Strong infection prevention programs are especially important in nursing homes where clusters of C. auris have already been discovered and where infection prevention and control resources have been lacking. According to the CDC, mortality rates attributable to invasive C. auris infection range from 30% to 59% globally, and from 22% to 57% in the U.S.”
“Time is of the essence because we may soon run out of options to treat infected patients. Healthcare facilities must dedicate resources and put plans in place to prevent pan-resistant C. auris from spreading in our hospitals and nursing homes.”
If you or a loved one suffered injuries (or worse) while in a healthcare facility in the United States due to an infection, medical neglect, or medical negligence, you should promptly find a medical malpractice lawyer in your state who may investigate your infection malpractice claim for you and represent you or your loved one in a medical malpractice case, if appropriate.
Visit our website to be connected with medical malpractice attorneys in your U.S. state who may assist you with your medical malpractice claim, or call us toll-free in the United States at 800-295-3959.
Turn to us when you don’t know where to turn.